Cancer is a group of complex genomic diseases. Today still most clinicians, patients, and policymakers think that precision oncology is the sequencing of cancer genomes, which is for many patients a fatal mistake. Here we present how a combination of multiple-omics approaches including a Luminex based multiplexed proteomics approach can help to identify not only better treatment regimen for the individual patient, but also biomarkers that may change the way how future patients will be treated.